Sunakiment
Sunakiment (AZD-8630) is a humanized IgG1λ monoclonal antibody inhibitor targeting thymic stromal lymphopoietin (TSLP), which enables direct airway delivery via a dry powder inhaler formulation. Sunakiment binds to TSLP and blocks its pro-inflammatory signal transduction. It is applicable to research on refractory asthma, asthma, and moderate-to-severe asthma.
For research use only. We do not sell to patients.
- CAS No.: 2928519-36-0
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
immunoglobulin Fab VH-G1(CH1-7h)_L-lambda2
Human
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Q969D9-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Fab-G1_lambda
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2928519-36-0
-
SMILES
N/A
-
Synonyms
AZD-8630
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Komori HK, et al. Potential of alarmin-targeted bispecific and combination therapies in airway disease. Frontiers in allergy. 2025;6:1700060. [Content Brief]
[3]. Doffman SR, et al. AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial. The Journal of allergy and clinical immunology. 2026 Apr 20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sunakiment Related Classifications
HY-P991717 Related Classifications
Powered by Bioz